American Cancer Society Steps Up Advocacy Activities

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

WASHINGTON--The American Cancer Society (ACS) has initiated a new, long-term advocacy program aimed at enhancing its influence on federal and state government actions that affect efforts to eliminate cancer.

WASHINGTON--The American Cancer Society (ACS) has initiated a new, long-termadvocacy program aimed at enhancing its influence on federal and stategovernment actions that affect efforts to eliminate cancer.

"There is simply no more effective way of helping society bringcancer under control than to work in concert with government," saidACS chief executive officer John R. Seffrin, PhD. "A single pieceof legislation, if it incorporates some action we know could save livesfrom cancer, can immediately impact the likelihood of avoiding or survivingcancer for literally millions of people."

Through its Advocacy Program, the society plans to build and use anextensive network of volunteers to promote and advance ACS positions, policies,and goals. The plan calls for regional and state affiliates to focus greaterattention on national, state, and local issues.

The society will also develop a clearing house for state ACS divisionsand local chapters to use in planning strategy and tracking pending legislationat both the state and federal levels.

Linda Hay Crawford, ACS' newly appointed national vice president forfederal and state government relations, will direct the program. Ms. Crawfordis the widow of Victor Crawford, a former tobacco industry lobbyist turnedantito-bacco crusader, who died of lung cancer.

Catherine R. Grant, a former National Rifle Association official, willdirect development of the grassroots network.

The new program will focus on eight areas viewed by the ACS as vitalto controlling cancer

Goals for ACS NEW Public Policy Advocacy Strategy

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content